Tagged: adaptive design

Clinical Research Now: One Foot in the 21st Century, the Other in Ancient Greece

We do 21st century biology in our laboratories and then do clinical trials that Hippocrates would have been quite comfortable with.  – Roger Perlmutter, executive vice president of Merck and president of Merck Research Laboratories, in a panel discussion at the Forbes Healthcare Summit in October. Perlmutter’s characterization of current clinical trials rings true.  Much… Read more »

Why Not Continuous Development?

While development of pharmaceutical products has traditionally followed a phased approach, a continuous model of development is possible and offers substantial reductions in development timelines and risk. Historical chokepoints demanded a “batched” approach during trials and between phases.  Many things have changed, but the chokepoints largely remain. It’s time to do something about them. The… Read more »

Amnesty for Reluctant Early Stoppers in Clinical Development

In the C-Suite, virtually all biopharma companies insist on failing unsuccessful candidates faster and reallocating resources to more promising molecules. This is only rational. But the industry has a dirty little secret. This isn’t the kind of secret that stays within the confines of the C-Suite. It’s the kind that never bubbles up that high…. Read more »

Faster to Market, Faster to Fail

The team at Health Decisions enjoys nothing more than helping a sponsor bring a successful product to market months or years ahead of schedule. Through a combination of adaptive design and adaptive operations, we have succeeded in accelerating market entry for many products, sometimes by more than two years, as in the case of one… Read more »